tectonic family member 2Genealiases: C12orf38 · JBTS24 · MKS8 · TECT2
Q-omics provides the consensus-scored TCTN2 profile across patient tissues and cancer cell-line models. TCTN2 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, TCTN2 is differentially expressed in 14, with the highest sampling consensus in BLCA. Additionally, TCTN2 RNA expression shows 20,019 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight SKCM, BLCA, and KIRP as cancer lineages where TCTN2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TCTN2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TCTN2 survival associations across molecular data types. TCTN2 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (5) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TCTN2 RNA expression–survival associations across cancer types. High TCTN2 expression shows unfavorable associations in LGG, KICH, LIHC and COAD, but favorable associations in SKCM and BRCA. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify SKCM as the clearest survival context for TCTN2 RNA expression.
This table summarizes TCTN2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for TCTN2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TCTN2 shows lower tumor expression in KICH and THCA and higher tumor expression in BLCA, KIRC, HNSC and COAD. The BLCA box plot shows higher TCTN2 RNA expression in tumor versus normal tissue (log2 FC = +1.044, t-test p < 0.001).
This table shows molecular features associated with TCTN2 in patient tissues and cancer cell lines. In patient samples, TCTN2 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, TCTN2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in SKIN and LARGE_INTESTINE.
